Pernix buys Zogenix's controversial pain drug Zohydro ER franchise
Executive Summary
Pernix Therapeutics Holdings Inc. bought Zogenix Inc.’s Zohydro ER (hydrocodone bitartrate capsules) assets for $100mm--$30mm cash, $20mm in Pernix stock (1.68mm shares), and a $50mm six-month promissory note--plus up to $12.5mm in regulatory and $271mm in pre-determined annual sales milestone targets of up to $1bn annually.
Deal Industry
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- Includes Equity
- Product Purchase
- R&D and Marketing (Licensing)
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice